Cholesterol Reduction: Materials provided for physicians to help educate patients

Download and print these customizable full-color handouts that you can give to your patients to help them manage their cholesterol and stay on top of their health goals.

Goal Tracker

Patients can use this goal card to keep track of their cholesterol goal over time. [31 KB, 1 page]

Preview

Diet Tips for Helping to Lower Cholesterol

Guides for your patients to use when shopping and eating. [1.72 MB, 1 page]

Preview

Exercise Tips for Helping to Lower Cholesterol

Benefits of daily physical activity and tips and ideas for exercise. [31 KB, 1 page]

Preview

If you would like to have your office contact information appear on the handouts, please fill in the fields below (all information is optional).

First Name:
Last Name:
Professional Designation:
Practice Name:
Practice Address:
City:
State:
ZIP:
Office Phone:
Office E-mail:
Office Web Site:	https://

Save Office Information*

Check to save your office contact information for future use on other patient handouts. Please see Merck’s Privacy Policy.

* Must have cookies enabled.

Your customized patient handout will appear in a new Web browser window, ready for you to print or save. If you have selected multiple handouts, they will appear as separate pages in the document. To make changes, simply close the PDF window and return to the “Patient Education Materials” page.

To view PDF documents, you must have Adobe Reader installed on your computer.

	The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
	ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough.
	Contraindications: hypersensitivity to any component of this medication.
	Statin contraindications apply when used with a statin: active liver disease; unexplained persistent elevations in hepatic transaminase levels. Statins are contraindicated in pregnant and nursing women. Refer to the statin label for details.
SELECTED CAUTIONARY INFORMATION
	When using ZETIA with a statin, also follow the label recommendations for that specific statin.
	When ZETIA was coadministered with a statin, consecutive elevations in hepatic transaminase levels (≥3 × ULN) were slightly higher (1.3%) than those of statins alone (0.4%). Liver function tests should be performed when ZETIA is added to statin therapy and according to statin recommendations. Should an increase in ALT or AST ≥3 × ULN persist, consider withdrawal of ZETIA and/or the statin.
	Patients should be advised to promptly report muscle pain, tenderness, or weakness. Risk for skeletal muscle toxicity increases with higher statin doses, advanced age (>65), hypothyroidism, renal impairment, and depending on the statin used, concomitant use of other drugs. Discontinue drug if myopathy is diagnosed or suspected.

Before prescribing ZETIA, please read the Prescribing Information.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

For non-US health care professionals, click here.

ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.

MerckMedicus™, MerckSource^®, and MerckServices^® are trademarks of Merck & Co., Inc.

Site Map | Privacy Policy | Terms & Conditions | Patient Assistance Program | Compliance Program

21050228(1)-06/10-ZET